Evidence map›Paper›PMID 37171699›Full record

ArticleActa diabetologica2023

No effects of COVID-19 on the development of type 1 diabetes autoimmunity and no evidence of an increased frequency of SARS-CoV-2 antibodies in newly diagnosed type 1 diabetes patients relative to healthy subjects.

Claudio Tiberti, Raffaella Nenna, Valeria Tromba, Tiziana Filardi, Laura Petrarca, Francesca Silvestri, Valeria Fassino, Monica Montuori, Enrica Mancino, Andrea Lenzi and 3 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Acta diabetologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Observational
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Claudio Tiberti *Department of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Raffaella Nenna *Department of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Valeria TrombaDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Tiziana FilardiDepartment of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Laura PetrarcaDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Francesca SilvestriDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Valeria FassinoDepartment of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Monica MontuoriDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Enrica MancinoDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Andrea LenziDepartment of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Fabio MidullaDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Francesco CostantinoDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
Susanna MoranoDepartment of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. susanna.morano@uniroma1.it.ORCID http://orcid.org/0000-0002-8156-9543
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate the relationship between SARS-CoV-2 infection and autoimmunity in type 1 diabetes (T1D) and SARS-CoV-2 antibodies frequency at diagnosis of T1D during pandemic.

methodsThe presence of T1D-specific autoimmunity was evaluated in a cohort of 99 children and adolescents without diabetes that contracted SARS-CoV-2 infection. Moreover, the frequency of IgM- and IgG-SARS-CoV-2 antibodies was evaluated in 41 newly diagnosed T1D patients not yet vaccinated against SARS-CoV-2 disease, collected during the pandemic, compared to healthy subjects (CTRL).

resultsNone of the 99 patients that contracted SARS-CoV-2 infection during the pandemic period was found positive for T1D autoantibodies. The frequency of SARS-CoV-2 antibodies was not significantly different in patients newly diagnosed with T1D (12.2%), compared with CTRL (8.4%). Among SARS-CoV-2 antibody positive T1D patients, 80% were target of diabetes autoantibodies and 60% had another concomitant autoimmune disease. Among the CTRL subjects positive for SARS-CoV-2Abs (n = 10), none was found positive for T1D autoantibodies.

conclusionsThe results of the present study do not confirm, at least in the short term, a role of COVID-19 as a potential trigger of T1D autoimmunity and do not provide evidence of an increased frequency of SARS-CoV-2 antibodies in newly diagnosed T1D patients in comparison with healthy population.

Indexed as

COVID-19Diabetes Mellitus, Type 1AdolescentAutoantibodiesAutoimmunityChildHealthy VolunteersHumansSARS-CoV-2AutoantibodiesAutoimmunityCOVID-19SARS-CoV-2SARS-CoV-2 antibodiesType 1 diabetes

Identifiers

PMID37171699
PMCPMC10175916
OpenAlexW4376224648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.